UBS/CALL/MODERNA/150.001/0.1/20.12.24 | Delayed Swiss Exchange 16:20:00 05/06/2024 BST | ||
| 2.3 CHF | +18.56% |
|
| Current month | +6.98% | ||
| 1 month | +112.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 2.3 | +18.56% |
| 04/06/24 | 1.94 | -13.00% |
| 03/06/24 | 2.23 | +3.72% |
| 31/05/24 | 2.15 | +7.50% |
| 30/05/24 | 2 | -0.50% |
Delayed Quote Swiss Exchange
Last update June 05, 2024 at 04:20 pm
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| PMRNDU | |
| ISIN | CH1310060913 |
| Date issued | 27/12/2023 |
| Strike | 150 $ |
| Maturity | 20/12/2024 (198 Days) |
| Parity | 10 : 1 |
| Emission price | 0.74 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.41 CHF |
|---|---|
| Lowest since issue | 0.32 CHF |
| Spread | 0.05 CHF |
| Spread % | 2.13% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8
USD
Average target price
142.8
USD
Spread / Average Target
-7.77%
- Stock Market
- Warrants
- PMRNDU Warrant
